← Leaderboards
Kelly E. Dooley
Vanderbilt University Medical Center
$16,423,496
Attributed
$33,268,809
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.2M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,568,905 · 10
FDA$3,699,904 · 2
By mechanism
UM1$14,399,999 · 1
R01$12,490,688 · 5
T32$2,279,619 · 1
R37$1,657,415 · 1
R56$817,252 · 1
K24$789,187 · 1
Top collaborators
- Anushka Naidoo10 shared
- Craig Walter Hendrix7 shared
- Eric L Nuermberger7 shared
- Susan E Dorman5 shared
- Radojka Savic2 shared
- Dirk Schnappinger2 shared
- Amita Gupta1 shared
- Olivier Marcy1 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Wayne A Ray$20,620,953
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsTuberculosis DrugsDoseTuberculosis TreatmentRegimenTuberculosisRifampinSafetyDrug InteractionsResistanceDrug ExposureFutureChildPlasmaDrug KineticsAreaTreatment ProtocolsClinical PharmacologyHiv/TbSamplingClinical TrialsMortalityAdultInvestigation
Grant awards (53)
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium$7,200,000
UM1 · FY2025 · AI
Short-course rifapentine for TB prevention for all: clinical pharmacology matters$813,899
R37 · FY2025 · AI · contact PI
Mentoring Investigators in HIV and Tuberculosis Therapeutics Research$119,225
K24 · FY2025 · AI · contact PI
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium$7,199,999
UM1 · FY2024 · AI
Short-course rifapentine for TB prevention for all: clinical pharmacology matters$843,516
R37 · FY2024 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$290,914
R01 · FY2024 · AI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$285,787
R01 · FY2024 · AI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$282,070
R01 · FY2024 · AI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$200,932
R01 · FY2024 · AI
Mentoring Investigators in HIV and Tuberculosis Therapeutics Research$119,225
K24 · FY2024 · AI · contact PI
Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV)$817,252
R56 · FY2023 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$369,940
R01 · FY2023 · AI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$303,515
R01 · FY2023 · AI
Mentoring Investigators in HIV and Tuberculosis Therapeutics Research$176,258
K24 · FY2023 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$129,848
R01 · FY2023 · AI
Clinical Pharmacology Training Program$385,532
T32 · FY2022 · GM
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$315,411
R01 · FY2022 · AI
Pharmacology and Pharmacometrics Core$164,293
P30 · FY2022 · AI · contact PI
Clinical Pharmacology Training Program$382,501
T32 · FY2021 · GM
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$330,027
R01 · FY2021 · AI
Mentoring Investigators in HIV and Tuberculosis Therapeutics Research$127,664
K24 · FY2021 · AI · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$100,000
R01 · FY2021 · FD · contact PI
Mentoring Investigators in HIV and Tuberculosis Therapeutics Research$65,484
K24 · FY2021 · AI · contact PI
Ph2a Study: Rifampin, Merrem, Augmentin for Tuberculosis IND 129159; 12/31/2015$499,999
R01 · FY2020 · FD · contact PI
Clinical Pharmacology Training Program$393,867
T32 · FY2020 · GM
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$346,580
R01 · FY2020 · AI
Mentoring Investigators in HIV and Tuberculosis Therapeutics Research$181,331
K24 · FY2020 · AI · contact PI
Ph2a Study: Rifampin, Merrem, Augmentin for Tuberculosis IND 129159; 12/31/2015$499,957
R01 · FY2019 · FD · contact PI
Innovative PK/PD Approaches to Optimize TBM Treatment in Children (PATCH Study)$487,818
R01 · FY2019 · HD · contact PI
Clinical Pharmacology Training Program$366,076
T32 · FY2019 · GM
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$718,961
R01 · FY2018 · AI
Ph2a Study: Rifampin, Merrem, Augmentin for Tuberculosis IND 129159; 12/31/2015$499,958
R01 · FY2018 · FD · contact PI
Innovative PK/PD Approaches to Optimize TBM Treatment in Children (PATCH Study)$496,233
R01 · FY2018 · HD · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2018 · FD · contact PI
Clinical Pharmacology Training Program$354,563
T32 · FY2018 · GM
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$748,871
R01 · FY2017 · AI
Innovative PK/PD Approaches to Optimize TBM Treatment in Children (PATCH Study)$500,491
R01 · FY2017 · HD · contact PI
Ph2a Study: Rifampin, Merrem, Augmentin for Tuberculosis IND 129159; 12/31/2015$499,990
R01 · FY2017 · FD · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2017 · FD · contact PI
Clinical Pharmacology Training Program$132,473
T32 · FY2017 · GM
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$668,698
R01 · FY2016 · AI
Clinical Pharmacology Training Program$264,607
T32 · FY2016 · GM
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$657,921
R01 · FY2015 · AI
Innovative PK/PD Approaches to Optimize TBM Treatment in Children (PATCH Study)$462,969
R01 · FY2015 · HD · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2015 · FD · contact PI
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$659,598
R01 · FY2014 · AI
Innovative PK/PD Approaches to Optimize TBM Treatment in Children (PATCH Study)$534,200
R01 · FY2014 · HD · contact PI
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis$400,000
R01 · FY2014 · FD · contact PI
PK/PD Issues in the Use of New Therapies for the Treatment of Tuberculosis$134,325
K23 · FY2013 · AI · contact PI
PK/PD Issues in the Use of New Therapies for the Treatment of Tuberculosis$134,325
K23 · FY2012 · AI · contact PI
PK/PD Issues in the Use of New Therapies for the Treatment of Tuberculosis$134,325
K23 · FY2011 · AI · contact PI
PK/PD Issues in the Use of New Therapies for the Treatment of Tuberculosis$133,807
K23 · FY2010 · AI · contact PI
PK/PD Issues in the Use of New Therapies for the Treatment of Tuberculosis$133,574
K23 · FY2009 · AI · contact PI